Payment overview · 2025
General Payments
$241.48
14 reported records · 10 companies
Healthcare provider profile · identity verified
William Chamberlain
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LOS ANGELES, CA · NPI 1760857247
Verified facts
What the public records show
CMS Open Payments records show William Chamberlain received $241.48 in general payments during 2025 across 14 reported records.
Antares Pharma, Inc. accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $84.21 | 34.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.34 | 11.3% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $21.87 | 9.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.46 | 8.1% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.45 | 6.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.04 | 6.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.70 | 6.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.39 | 6.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.05 | 5.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.97 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $241.48 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $84.21 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.34 | 2 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 548 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 483 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 465 | 127 |
| Meloxicam | Meloxicam | 399 | 101 |
| Losartan Potassium | Losartan Potassium | 386 | 105 |
| Prednisone | Prednisone | 369 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 89 |
| Lisinopril | Lisinopril | 330 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 325 | 129 |
| Metformin Hcl | Metformin Hcl | 294 | 79 |
| Gabapentin | Gabapentin | 271 | 65 |
| Furosemide | Furosemide | 247 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 246 | 48 |
| Potassium Chloride | Potassium Chloride | 245 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 241 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 241 | 65 |
| Alprazolam | Alprazolam | 224 | 34 |
| Omeprazole | Omeprazole | 218 | 42 |
| Estradiol | Estradiol | 205 | 39 |
| Allopurinol | Allopurinol | 202 | 52 |
| Azithromycin | Azithromycin | 200 | 138 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 47 |
| Fluconazole | Fluconazole | 176 | 88 |
| Famotidine | Famotidine | 164 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 151 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 36 |
| Tramadol Hcl | Tramadol Hcl | 142 | 31 |
| Memantine Hcl | Memantine Hcl | 141 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 73 |
| Progesterone | Progesterone, Micronized | 126 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 39 |
| Simvastatin | Simvastatin | 114 | 28 |
| Montelukast Sodium | Montelukast Sodium | 103 | 24 |
| Ezetimibe | Ezetimibe | 99 | 26 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 98 | 19 |
| Ozempic | Semaglutide | 96 | 18 |
| Trazodone Hcl | Trazodone Hcl | 94 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 23 |
| Baclofen | Baclofen | 89 | 28 |
| Finasteride | Finasteride | 87 | 24 |
| Spironolactone | Spironolactone | 86 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 85 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 84 | 27 |
| Diazepam | Diazepam | 82 | 16 |
| Atenolol | Atenolol | 81 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 20 |
| Temazepam | Temazepam | 80 | 20 |
| Eliquis | Apixaban | 76 | 16 |
| Ketoconazole | Ketoconazole | 76 | 31 |
| Carvedilol | Carvedilol | 73 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 73 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 12 |
| Glipizide | Glipizide | 69 | 15 |
| Ibuprofen | Ibuprofen | 67 | 24 |
| Anastrozole | Anastrozole | 65 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 61 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 13 |
| Pregabalin | Pregabalin | 60 | 12 |
| Chlorthalidone | Chlorthalidone | 59 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 11 |
| Aripiprazole | Aripiprazole | 56 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Lorazepam | Lorazepam | 52 | 12 |
| Metformin Hcl Er | Metformin Hcl | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | 11 |
| Celecoxib | Celecoxib | 51 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Rybelsus | Semaglutide | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 16 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Metronidazole | Metronidazole | 39 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Fenofibrate | Fenofibrate,micronized | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Nystatin | Nystatin | 32 | 20 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 13 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | 11 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 20 |
| Lactulose | Lactulose | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Metaxalone | Metaxalone | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $241.48 · 14 records | Antares Pharma, Inc. | CREON, Evoke, FARXIGA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, Ozempic, Rybelsus, Tlando, VOQUEZNA, XYOSTED | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error